Shares of ContraVir Pharmaceuticals $CTRV soared in premarket trading in response to its announcement of an encouraging interim results from a Phase 2 a multiple ascending dose trial evaluating CMX157 compared to Gilead Sciences� $GILD Viread (tenofovir disoproxil fumarate or TDF) for the treatment of chronic hepatitis B virus (HBV) infection. Data from 10 HBV-positive patients who took once-daily dose of 25 mg of CMX157 and two patients who received 300 mg of Viread once-daily for 14 days showed an average 99% reduction in HBV viral load compared to baseline.